Clinically available osteoporosis treatments such as hormone replacement therapy, bisphosphates, and RANKL antibody have acceptable therapeutic outcome by exhibiting an appreciated suppression on bone resorption. This evidence concerns the gene TNFSF11 and osteoporosis.